Sandoz Group AG | WebDisclosure

Basculer en Français

9472	Companies
185370	Keywords
117721	Articles
99262	Press releases

Home
Companies
Sandoz Group AG

BRIEF

published on 11/12/2025 at 07:40, 22 days 23 hours ago

Sandoz obtient une licence mondiale pour un biosimilaire du cancer du sein

Oncologie Biosimilaire Cancer Du Sein Sandoz Pertuzumab
PRESS RELEASE

published on 11/12/2025 at 07:35, 22 days 23 hours ago

Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab
Sandoz signs global license agreement with EirGenix Inc. to commercialize biosimilar pertuzumab for HER2-positive breast cancer treatment, reinforcing its position in oncology

Agreement Biosimilar Breast Cancer Sandoz Pertuzumab
BRIEF

published on 11/04/2025 at 22:10, 1 month ago

Sandoz acquiert Just-Evotec Biologics pour développer ses capacités dans le domaine des biosimilaires.

Acquisition Biosimilaires Toulouse Sandoz Just-Evotec
BRIEF

published on 11/04/2025 at 22:10, 1 month ago

Sandoz Acquires Just-Evotec Biologics to Expand Biosimilars Capabilities

Acquisition Biosimilars Toulouse Sandoz Just-Evotec
PRESS RELEASE

published on 11/04/2025 at 22:05, 1 month ago

Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse
Sandoz strengthens biosimilars capabilities with acquisition of Just-Evotec Biologics EU SAS in Toulouse. Acquisition aims to capture projected biosimilar market opportunity. Transaction includes cash payment and technology license fees

Acquisition Biosimilars Sandoz Just-Evotec Biologics Continuous Manufacturing Technology
BRIEF

published on 10/30/2025 at 07:05, 1 month 6 days ago

Sandoz annonce une croissance de ses ventes et une révision à la hausse de ses prévisions de marge.

Croissance Des Ventes Biosimilaires Performance Régionale Orientation Financière Questions Commerciales
BRIEF

published on 10/30/2025 at 07:05, 1 month 6 days ago

Sandoz Reports Growth in Sales and Upgraded Margin Guidance

Financial Guidance Sales Growth Biosimilars Regional Performance Trade Issues
PRESS RELEASE

published on 10/30/2025 at 07:00, 1 month 6 days ago

Sandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded
Sandoz reports 5% growth in net sales for 9 months, with biosimilars contributing over 30%. Full-year margin guidance raised to 21-22% core EBITDA

EBITDA Net Sales Biosimilars Sandoz Margin Guidance
BRIEF

published on 09/09/2025 at 07:05, 2 months 26 days ago

Sandoz et Regeneron règlent un litige en matière de brevets

Approbation De La FDA Biosimilaire Sandoz Regeneron Aflibercept
BRIEF

published on 09/09/2025 at 07:05, 2 months 26 days ago

Sandoz and Regeneron Resolve Patent Dispute

FDA Approval Biosimilar Sandoz Regeneron Aflibercept

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 50 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 55 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 6 hours 25 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 20 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 25 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 07:00, 24 minutes ago

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 54 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 34 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 59 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 10 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025

Les Echos

Published on 12/04/2025 at 18:14, 13 hours 10 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 25 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 25 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 40 minutes ago

Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 40 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE